{"id":24446,"date":"2025-11-25T10:23:40","date_gmt":"2025-11-25T10:23:40","guid":{"rendered":"https:\/\/itbusinesstoday.com\/?p=24446"},"modified":"2025-11-25T10:23:40","modified_gmt":"2025-11-25T10:23:40","slug":"otsuka-files-fda-application-for-centanafadine-adhd-drug","status":"publish","type":"post","link":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/otsuka-files-fda-application-for-centanafadine-adhd-drug\/","title":{"rendered":"\u5927\u585a\u88fd\u85ac\u3001ADHD\u6cbb\u7642\u85ac\u300c\u30bb\u30f3\u30bf\u30ca\u30d5\u30a1\u30b8\u30f3\u300d\u3092FDA\u306b\u7533\u8acb"},"content":{"rendered":"<?xml encoding=\"utf-8\" ?><p>\u5927\u585a\u30d5\u30a1\u30fc\u30de\u30b7\u30e5\u30fc\u30c6\u30a3\u30ab\u30eb\u30c7\u30a3\u30d9\u30ed\u30c3\u30d7\u30e1\u30f3\u30c8\uff06\u30b3\u30de\u30fc\u30b7\u30e3\u30ea\u30bc\u30fc\u30b7\u30e7\u30f3\u682a\u5f0f\u4f1a\u793e\u3068 <a href=\"https:\/\/www.otsuka.co.jp\/\" data-no-translation=\"\">Otsuka Pharmaceutical Co<\/a>.Ltd.\u306f\u3001\u65b0\u898f\u306e\u30ce\u30eb\u30a8\u30d4\u30cd\u30d5\u30ea\u30f3\u30fb\u30c9\u30d1\u30df\u30f3\u30fb\u30bb\u30ed\u30c8\u30cb\u30f3\u518d\u53d6\u308a\u8fbc\u307f\u963b\u5bb3\u5264\uff08NDSRI\uff09\u3067\u3042\u308b\u30bb \u30f3\u30bf\u30ca\u30d5\u30a1\u30b8\u30f31\u65e51\u56de\u5f90\u653e\u30ab\u30d7\u30bb\u30eb\u306b\u3064\u3044\u3066\u3001\u5c0f\u5150\u30fb\u9752\u5e74\u30fb\u6210\u4eba\u306e\u6ce8\u610f\u6b20\u9665\u591a\u52d5\u6027\u969c\u5bb3\uff08ADHD\uff09\u6cbb\u7642\u85ac\u3068\u3057\u3066\u3001\u7c73 \u56fd\u98df\u54c1\u533b\u85ac\u54c1\u5c40\uff08FDA\uff09\u306b\u65b0\u85ac\u627f\u8a8d\u7533\u8acb\u3092\u884c\u3063\u305f\u3053\u3068\u3092\u767a\u8868\u3057\u307e\u3057\u305f\u3002\u672c\u85ac\u306eNDA\u7533\u8acb\u306f\u3001\u60a3\u8005\u96c6\u56e3\u306b\u304a\u3051\u308b\u6709\u52b9\u6027\u3068\u5b89\u5168\u6027\u3092\u8a55\u4fa1\u3059\u308b4\u3064\u306e\u91cd\u8981\u306a\u81e8\u5e8a\u7b2c3\u76f8\u8a66\u9a13\u306e\u7d50\u679c\u306b\u57fa\u3065\u3044\u3066\u3044\u307e\u3059\u3002.<\/p><p>&ldquo;As an innovator in mental health, we are pleased to take this important step forward in the hope of providing a novel treatment option to patients living with ADHD,&rdquo; said John Kraus, M.D., Ph.D., executive vice president and chief medical officer, Otsuka Pharmaceutical Development &amp; Commercialization, Inc. &ldquo;Centanafadine represents a first in class mechanism of action among available ADHD therapies, and if approved, may expand the range of options available to those managing this complex condition. We are grateful to the patients and caregivers for their participation in these trials.&rdquo;<\/p><p>In Phase 3 clinical studies with children, adolescents, and adults, centanafadine demonstrated statistically significant and clinically meaningful improvements in ADHD symptoms compared with placebo, as measured by the ADHD Rating Scale &ndash; 5 (ADHD-RS-5) in adolescents and children, and the ADHD Investigator Symptom Rating Scale (AISRS) in adults. Centanafadine was generally well tolerated across studies, with the most common adverse events including decreased appetite, nausea, rash, fatigue, abdominal pain, and somnolence in children and adolescents, and decreased appetite and headache in adults.<\/p><h4>\u3053\u3061\u3089\u3082\u304a\u8aad\u307f\u304f\u3060\u3055\u3044\uff1a <a class=\"p-url\" href=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/emulate-and-fujifilm-unveil-brain-chip-r1\/\" rel=\"bookmark\">\u30a8\u30df\u30e5\u30ec\u30fc\u30c8\u3068\u5bcc\u58eb\u30d5\u30a4\u30eb\u30e0\u3001\u30d6\u30ec\u30a4\u30f3\u30c1\u30c3\u30d7R1\u3092\u767a\u8868<\/a><\/h4><h4>\u7b2c3\u76f8\u81e8\u5e8a\u8a66\u9a13\u30d7\u30ed\u30b0\u30e9\u30e0\u306b\u3064\u3044\u3066<\/h4><p>Centanafadine \u306e\u30d5\u30a7\u30fc\u30ba 3 \u30d7\u30ed\u30b0\u30e9\u30e0\u306f\u3001\u521d\u306e NDSRI ADHD \u6cbb\u7642\u85ac\u306e\u78ba\u56fa\u305f\u308b\u81e8\u5e8a\u8a55\u4fa1\u3092\u63d0\u4f9b\u3059\u308b\u3082\u306e\u3067\u3059\u3002\u3053\u306e\u81e8\u5e8a\u30d7\u30ed\u30b0\u30e9\u30e0\u306f\u3001\u5c0f\u5150\u3001\u9752\u5e74\u3001\u6210\u4eba\u306b\u304a\u3051\u308bcentanafadine\u306e\u6709\u52b9\u6027\u3068\u5b89\u5168\u6027\u3092\u8a55\u4fa1\u3059\u308b4\u3064\u306e\u91cd\u8981\u306a\u7b2c3\u76f8\u8a66\u9a13\u3067\u69cb\u6210\u3055\u308c\u3066\u3044\u307e\u3059\u3002.<\/p><p>\u5c0f\u5150\u3092\u5bfe\u8c61\u3068\u3057\u305f\u91cd\u8981\u306a\u7b2c3\u76f8\u8a66\u9a13\uff08NCT05428033\uff09\u306f\u3001ADHD\u3092\u6709\u3059\u308b4\uff5e12\u6b73\u306e\u5c0f\u5150\u3092\u5bfe\u8c61\u306b\u3001centanafadine\u306e\u6709\u52b9\u6027\u3001\u5b89\u5168\u6027\u3001\u5fcd\u5bb9\u6027\u3092\u8a55\u4fa1\u3059\u308b\u7121\u4f5c\u70ba\u5316\u4e8c\u91cd\u76f2\u691c3\u7fa4\u56fa\u5b9a\u7528\u91cf\u8a66\u9a13\u3067\u3059\u3002\u53c2\u52a0\u8005\u306f\u3001\u4f53\u91cd\u306b\u5fdc\u3058\u305f\u9ad8\u7528\u91cf\u3001\u4f4e\u7528\u91cf\u3001\u307e\u305f\u306f\u30d7\u30e9\u30bb\u30dc\u30926\u9031\u9593\u6295\u4e0e\u3055\u308c\u307e\u3057\u305f\u3002\u4e3b\u8981\u8a55\u4fa1\u9805\u76ee\u306f\u30016\u9031\u76ee\u306b\u304a\u3051\u308bADHD-RS-5\u7dcf\u5408\u30b9\u30b3\u30a2\u306e\u30d9\u30fc\u30b9\u30e9\u30a4\u30f3\u304b\u3089\u306e\u5909\u5316\u3002\u9ad8\u7528\u91cf\u7fa4\u306f\u30d7\u30e9\u30bb\u30dc\u7fa4\u306b\u5bfe\u3057\u3066\u7d71\u8a08\u5b66\u7684\u306b\u6709\u610f\u306a\u6539\u5584\u3092\u793a\u3057\u3001\u4f4e\u7528\u91cf\u7fa4\u306f\u7d71\u8a08\u5b66\u7684\u6709\u610f\u5dee\u306b\u9054\u3057\u307e\u305b\u3093\u3067\u3057\u305f\u3002\u672c\u85ac\u306e\u5b89\u5168\u6027\u304a\u3088\u3073\u5fcd\u5bb9\u6027\u30d7\u30ed\u30d5\u30a1\u30a4\u30eb\u306f\u826f\u597d\u3067\u3001\u4e71\u7528\u3084\u4f9d\u5b58\u306e\u53ef\u80fd\u6027\u306f\u4f4e\u304f\u3001\u6700\u3082\u591a\u304f\u5831\u544a\u3055\u308c\u305f\u6709\u5bb3\u4e8b\u8c61\u306f\u3001\u98df\u6b32\u6e1b\u9000\u3001\u767a\u75b9\u3001\u5614\u5410\u306a\u3069\u3067\u3057\u305f\u3002.<\/p><p>\u9752\u5c11\u5e74\u3092\u5bfe\u8c61\u3068\u3057\u305f\u91cd\u8981\u306a\u7b2c3\u76f8\u8a66\u9a13\uff08NCT05257265\uff09\u306f\u300113\uff5e17\u6b73\u306eADHD\u3092\u6709\u3059\u308b\u9752\u5c11\u5e74\u3092\u5bfe\u8c61\u306b\u3001centanafadine\u306e\u6709\u52b9\u6027\u3001\u5b89\u5168\u6027\u3001\u5fcd\u5bb9\u6027\u3092\u8a55\u4fa1\u3059\u308b\u305f\u3081\u306b\u30c7\u30b6\u30a4\u30f3\u3055\u308c\u305f\u7121\u4f5c\u70ba\u5316\u3001\u4e8c\u91cd\u76f2\u691c\u30013\u7fa4\u56fa\u5b9a\u7528\u91cf\u8a66\u9a13\u3067\u3059\u3002\u53c2\u52a0\u8005\u306f6\u9031\u9593\u306e\u6cbb\u7642\u671f\u9593\u4e2d\u3001\u9ad8\u7528\u91cf\u3001\u4f4e\u7528\u91cf\u307e\u305f\u306f\u30d7\u30e9\u30bb\u30dc\u306e\u3044\u305a\u308c\u304b\u3092\u6295\u4e0e\u3055\u308c\u307e\u3057\u305f\u3002\u4e3b\u8981\u8a55\u4fa1\u9805\u76ee\u306f\u30016\u9031\u76ee\u306eADHD\u8a55\u4fa1\u5c3a\u5ea6-5\uff08ADHD-RS-5\uff09\u7dcf\u5408\u30b9\u30b3\u30a2\u306e\u30d9\u30fc\u30b9\u30e9\u30a4\u30f3\u304b\u3089\u306e\u5909\u5316\u3002\u9ad8\u7528\u91cf\u7fa4\u3067\u306f\u3001\u30d7\u30e9\u30bb\u30dc\u7fa4\u3068\u6bd4\u8f03\u3057\u3066ADHD\u75c7\u72b6\u304c\u7d71\u8a08\u5b66\u7684\u306b\u6709\u610f\u304b\u3064\u81e8\u5e8a\u7684\u306b\u610f\u7fa9\u306e\u3042\u308b\u6e1b\u5c11\u3092\u793a\u3057\u307e\u3057\u305f\u3002Centanafadine \u306e\u5b89\u5168\u6027\u304a\u3088\u3073\u5fcd\u5bb9\u6027\u30d7\u30ed\u30d5\u30a1\u30a4\u30eb\u306f\u826f\u597d\u3067\u3001\u4e71\u7528\u3084\u4f9d\u5b58\u306e\u53ef\u80fd\u6027\u306f\u4f4e\u304f\u3001\u4e3b\u306a\u6709\u5bb3\u4e8b\u8c61\u306f\u98df\u6b32\u6e1b\u9000\u3001\u60aa\u5fc3\u3001\u982d\u75db\u3001\u767a\u75b9\u306a\u3069\u3067\u3057\u305f\u3002.<\/p><p>\u6210\u4eba\u3092\u5bfe\u8c61\u3068\u3057\u305f2\u3064\u306e\u91cd\u8981\u306a\u7b2c3\u76f8\u8a66\u9a13\uff08NCT03605680\u3001NCT03605836\uff09\u306f\u3001ADHD\u3092\u6709\u3059\u308b18\uff5e55\u6b73\u306e\u6210\u4eba\u3092\u5bfe\u8c61\u306b\u3001centanafadine\u5f90\u653e\u9320\uff08SR\uff09\u306e\u6709\u52b9\u6027\u3001\u5b89\u5168\u6027\u3001\u5fcd\u5bb9\u6027\u3092\u8a55\u4fa1\u3059\u308b\u305f\u3081\u306b\u30c7\u30b6\u30a4\u30f3\u3055\u308c\u305f\u7121\u4f5c\u70ba\u5316\u4e8c\u91cd\u76f2\u691c\u30d7\u30e9\u30bb\u30dc\u5bfe\u7167\u8a66\u9a13\u3067\u3059\u3002\u53c2\u52a0\u8005\u306f\u30016\u9031\u9593\u306e\u6cbb\u7642\u671f\u9593\u4e2d\u3001centanafadine 200mg\/\u65e5\u3001400mg\/\u65e5\u3001\u307e\u305f\u306f\u30d7\u30e9\u30bb\u30dc\u306e\u3044\u305a\u308c\u304b\u3092\u6295\u4e0e\u3055\u308c\u307e\u3057\u305f\u3002\u4e3b\u8981\u8a55\u4fa1\u9805\u76ee\u306f\u30016\u9031\u76ee\u306b\u304a\u3051\u308b\u6210\u4ebaADHD\u8abf\u67fb\u8005\u75c7\u72b6\u8a55\u4fa1\u5c3a\u5ea6\uff08AISRS\uff09\u5408\u8a08\u30b9\u30b3\u30a2\u306e\u30d9\u30fc\u30b9\u30e9\u30a4\u30f3\u304b\u3089\u306e\u5909\u5316\u3067\u3057\u305f\u3002\u4e21\u7fa4\u3068\u3082\u30d7\u30e9\u30bb\u30dc\u306b\u5bfe\u3057\u3066\u7d71\u8a08\u5b66\u7684\u306b\u6709\u610f\u304b\u3064\u81e8\u5e8a\u7684\u306b\u610f\u7fa9\u306e\u3042\u308b\u6539\u5584\u3092\u793a\u3057\u307e\u3057\u305f\u3002\u4e21\u8a66\u9a13\u306b\u304a\u3044\u3066\u3001centanafadine\u306f\u826f\u597d\u306a\u5b89\u5168\u6027\u304a\u3088\u3073\u5fcd\u5bb9\u6027\u30d7\u30ed\u30d5\u30a1\u30a4\u30eb\u3092\u793a\u3057\u3001\u4e71\u7528\u3084\u4f9d\u5b58\u306e\u53ef\u80fd\u6027\u306f\u4f4e\u304f\u3001\u6700\u3082\u4e00\u822c\u7684\u306a\u6709\u5bb3\u4e8b\u8c61\u306f\u98df\u6b32\u6e1b\u9000\u3001\u982d\u75db\u306a\u3069\u3067\u3057\u305f\u3002.<\/p><p><strong>\u30bd\u30fc\u30b9 <a href=\"https:\/\/www.businesswire.com\/news\/home\/20251124043308\/en\/Otsuka-Pharmaceutical-Submits-New-Drug-Application-to-U.S.-FDA-for-Centanafadine-for-the-Treatment-of-ADHD-in-Children-Adolescents-and-Adults\" data-no-translation=\"\">BusinessWire<\/a><\/strong><\/p>","protected":false},"excerpt":{"rendered":"<p>Otsuka Pharmaceutical Development &amp; Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. announce the filing of a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for centanafadine, once daily extended release capsules, a novel norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI), for the treatment of attention-deficit hyperactivity disorder (ADHD) in children, adolescents, and adults. The NDA submission is supported by results from four pivotal Phase 3 clinical trials evaluating the efficacy and safety of centanafadine across patient populations.&ldquo;As an innovator in mental health, we are pleased to take this important step forward in the hope of providing a novel treatment option to patients living with ADHD,&rdquo; said [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":24447,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"wprm-recipe-roundup-name":"","wprm-recipe-roundup-description":"","postBodyCss":"","postBodyMargin":[],"postBodyPadding":[],"postBodyBackground":{"backgroundType":"classic","gradient":""},"footnotes":""},"categories":[208,89,211,237,182,206],"tags":[9355,9354,5251,1433,424],"ppma_author":[205],"class_list":["post-24446","post","type-post","status-publish","format-standard","has-post-thumbnail","category-apac","category-health-tech","category-japan","category-news","category-pharma","category-regional","tag-centanafadine","tag-drug-application","tag-general-health","tag-otsuka-pharmaceutical","tag-pharma"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Otsuka Seeks FDA OK for Centanafadine ADHD Treatment<\/title>\n<meta name=\"description\" content=\"Otsuka filed an NDA with the FDA for centanafadine (an NDSRI) for the once-daily treatment of ADHD in children, adolescents, and adults.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/otsuka-files-fda-application-for-centanafadine-adhd-drug\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Otsuka Seeks FDA OK for Centanafadine ADHD Treatment\" \/>\n<meta property=\"og:description\" content=\"Otsuka filed an NDA with the FDA for centanafadine (an NDSRI) for the once-daily treatment of ADHD in children, adolescents, and adults.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/otsuka-files-fda-application-for-centanafadine-adhd-drug\/\" \/>\n<meta property=\"og:site_name\" content=\"itbusinesstoday\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-25T10:23:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/11\/Otsuka-Pharmaceutical-Submits-New-Drug-Application-to-U.S.-FDA-for-Centanafadine-for-the-Treatment-of-ADHD-in-Children_-Adolescents_-and-Adults.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NewsDesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"NewsDesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"4\u5206\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u5927\u585a\u88fd\u85ac\u3001ADHD\u6cbb\u7642\u85ac\u300c\u30bb\u30f3\u30bf\u30ca\u30d5\u30a1\u30b8\u30f3\u300d\u306eFDA\u627f\u8a8d\u7533\u8acb\u306b\u3064\u3044\u3066","description":"\u5927\u585a\u88fd\u85ac\u306f\u3001\u5c0f\u5150\u3001\u9752\u5e74\u304a\u3088\u3073\u6210\u4eba\u306b\u304a\u3051\u308b1\u65e51\u56de\u6295\u4e0e\u306eADHD\u6cbb\u7642\u85ac\u3068\u3057\u3066\u3001\u30bb \u30f3\u30bf\u30ca\u30d5\u30a1\u30b8\u30f3\uff08NDSRI\uff09\u306e\u65b0\u85ac\u627f\u8a8d\u7533\u8acb\u3092FDA\u306b\u63d0\u51fa\u3057\u307e\u3057\u305f\u3002.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/otsuka-files-fda-application-for-centanafadine-adhd-drug\/","og_locale":"ja_JP","og_type":"article","og_title":"Otsuka Seeks FDA OK for Centanafadine ADHD Treatment","og_description":"Otsuka filed an NDA with the FDA for centanafadine (an NDSRI) for the once-daily treatment of ADHD in children, adolescents, and adults.","og_url":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/otsuka-files-fda-application-for-centanafadine-adhd-drug\/","og_site_name":"itbusinesstoday","article_published_time":"2025-11-25T10:23:40+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/11\/Otsuka-Pharmaceutical-Submits-New-Drug-Application-to-U.S.-FDA-for-Centanafadine-for-the-Treatment-of-ADHD-in-Children_-Adolescents_-and-Adults.webp","type":"image\/webp"}],"author":"NewsDesk","twitter_card":"summary_large_image","twitter_misc":{"\u57f7\u7b46\u8005":"NewsDesk","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"4\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/otsuka-files-fda-application-for-centanafadine-adhd-drug\/#article","isPartOf":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/otsuka-files-fda-application-for-centanafadine-adhd-drug\/"},"author":{"name":"NewsDesk","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/d58d81f55e8acd257ab63d49fb4ea812"},"headline":"Otsuka Files FDA application for Centanafadine ADHD Drug","datePublished":"2025-11-25T10:23:40+00:00","mainEntityOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/otsuka-files-fda-application-for-centanafadine-adhd-drug\/"},"wordCount":639,"publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/otsuka-files-fda-application-for-centanafadine-adhd-drug\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/11\/Otsuka-Pharmaceutical-Submits-New-Drug-Application-to-U.S.-FDA-for-Centanafadine-for-the-Treatment-of-ADHD-in-Children_-Adolescents_-and-Adults.webp","keywords":["Centanafadine","Drug application","General health","Otsuka Pharmaceutical","Pharma"],"articleSection":["APAC","Health Tech","Japan","News","Pharma","Regional"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/otsuka-files-fda-application-for-centanafadine-adhd-drug\/","url":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/otsuka-files-fda-application-for-centanafadine-adhd-drug\/","name":"\u5927\u585a\u88fd\u85ac\u3001ADHD\u6cbb\u7642\u85ac\u300c\u30bb\u30f3\u30bf\u30ca\u30d5\u30a1\u30b8\u30f3\u300d\u306eFDA\u627f\u8a8d\u7533\u8acb\u306b\u3064\u3044\u3066","isPartOf":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website"},"primaryImageOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/otsuka-files-fda-application-for-centanafadine-adhd-drug\/#primaryimage"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/otsuka-files-fda-application-for-centanafadine-adhd-drug\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/11\/Otsuka-Pharmaceutical-Submits-New-Drug-Application-to-U.S.-FDA-for-Centanafadine-for-the-Treatment-of-ADHD-in-Children_-Adolescents_-and-Adults.webp","datePublished":"2025-11-25T10:23:40+00:00","description":"\u5927\u585a\u88fd\u85ac\u306f\u3001\u5c0f\u5150\u3001\u9752\u5e74\u304a\u3088\u3073\u6210\u4eba\u306b\u304a\u3051\u308b1\u65e51\u56de\u6295\u4e0e\u306eADHD\u6cbb\u7642\u85ac\u3068\u3057\u3066\u3001\u30bb \u30f3\u30bf\u30ca\u30d5\u30a1\u30b8\u30f3\uff08NDSRI\uff09\u306e\u65b0\u85ac\u627f\u8a8d\u7533\u8acb\u3092FDA\u306b\u63d0\u51fa\u3057\u307e\u3057\u305f\u3002.","breadcrumb":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/otsuka-files-fda-application-for-centanafadine-adhd-drug\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/itbusinesstoday.com\/health-tech\/pharma\/otsuka-files-fda-application-for-centanafadine-adhd-drug\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/otsuka-files-fda-application-for-centanafadine-adhd-drug\/#primaryimage","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/11\/Otsuka-Pharmaceutical-Submits-New-Drug-Application-to-U.S.-FDA-for-Centanafadine-for-the-Treatment-of-ADHD-in-Children_-Adolescents_-and-Adults.webp","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/11\/Otsuka-Pharmaceutical-Submits-New-Drug-Application-to-U.S.-FDA-for-Centanafadine-for-the-Treatment-of-ADHD-in-Children_-Adolescents_-and-Adults.webp","width":1200,"height":800,"caption":"Otsuka Pharmaceutical"},{"@type":"BreadcrumbList","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/otsuka-files-fda-application-for-centanafadine-adhd-drug\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/itbusinesstoday.com\/"},{"@type":"ListItem","position":2,"name":"Otsuka Files FDA application for Centanafadine ADHD Drug"}]},{"@type":"WebSite","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","description":"","publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","width":663,"height":275,"caption":"itbusinesstoday"},"image":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/d58d81f55e8acd257ab63d49fb4ea812","name":"\u30cb\u30e5\u30fc\u30b9\u30c7\u30b9\u30af","image":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png74f313ad3d6fa27a1eee85c30be63d03","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png","caption":"NewsDesk"},"sameAs":["https:\/\/itbusinesstoday.com"],"url":"https:\/\/itbusinesstoday.com\/ja\/author\/newsdesk\/"}]}},"authors":[{"term_id":205,"user_id":4,"is_guest":0,"slug":"newsdesk","display_name":"NewsDesk","avatar_url":{"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png","url2x":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png"},"author_category":"","first_name":"NewsDesk","last_name":"","user_url":"https:\/\/itbusinesstoday.com","job_title":"","description":""}],"_links":{"self":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/24446","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/comments?post=24446"}],"version-history":[{"count":1,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/24446\/revisions"}],"predecessor-version":[{"id":24448,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/24446\/revisions\/24448"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media\/24447"}],"wp:attachment":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media?parent=24446"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/categories?post=24446"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/tags?post=24446"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/ppma_author?post=24446"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}